The Vancouver-based biotech company said it has developed an antibody to provide non-hormonal treatments for hot flashes, a menopause symptom experienced by up to 80 per cent of women. The trial followed 92 women and found a statistically significant reduction in frequency and severity of hot flashes after four weeks. (The Logic)
Talking point: AbCellera, which made a global name for itself by developing an early treatment for COVID-19, has been searching for its first “winning drug” that could transform it into a global biotech company, CEO Carl Hansen said on a conference call about the trial’s results. Hansen is now betting that the ABCL635 antibody could be that product. AbCellera is developing the treatment for patients who need non-hormonal treatments for hot flashes, such as cancer patients undergoing hormone deprivation, or patients experiencing chronic insomnia. Victoria-based OBGYN Kelsey Mills, who joined AbCellera’s conference call, said addressing insomnia could have “a massive impact” on both women’s health and economic output.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.